07 April 2021 | News
New Silkroutes group Acclivis signs MoU to develop GEIA™ platform that can pulls genomics data from cloud data storage to produce clinical reports for medical practitioners and clinicians
Photo Credit: Freepik
Singapore's New Silkroutes Group Limited (NSG) has signed a Memorandum of Understanding (MOU) with Acclivis Technologies and Solutions Pte Ltd (Acclivis) to design and develop a comprehensive workflow for a cloud-based artificial intelligence (AI) platform that can be used to provide genomic-driven healthcare.
NSG, which operates a network of medical and dental clinics in Singapore, will own the intellectual property rights for the workflow and UI/UX (user interface/user experience). NSG plans to develop an AI platform that will be able to pull genomics data from cloud data storage for use in different data analysis modules. The system will then produce customised clinical reports for medical practitioners and clinicians. As the system has machine learning capability, it should become more intelligent with time and increased utilization.
Dr VicPearly Wong, NSG’s Chief Executive Officer, said: “We have been working hard to enhance our AI capabilities to transform ourselves into a tech-enabled healthcare group that will provide patients with the best diagnosis and treatment. We look forward to launching GEIATM, our very own AI solution soon. GEIATM is a complete and seamless, hybrid cloud-based workflow platform solution with AI-optimised analyses”
Acclivis is a leading enterprise cloud and IT services provider that uses disruptive technologies such as AI and machine learning to help organizations embark on digital transformation and innovation in Asia Pacific. Acclivis will also help build a private AI cloud facility and develop a secure network connection within NSG operational facilities.
Marcus Cheng, CEO of Acclivis, said: “Acclivis has a track record of building and managing private cloud facilities and developing AI technology platforms that define the structure and automate workflows for the public, commercial and healthcare sectors.”
In first quarter of the year, NSG has entered into collaborations with two global technology giants to develop an AI platform that can be used in genomics-driven healthcare, including building predictive models for cancer and other ailments.